Study of ESR1 Mutations in Metastatic Breast Cancer

计划入组 104 人 · 首次发布于 2015 年 6 月 16 日

Immunologic Targeting of ESR1 Receptor for Hormone Receptor Expressing Metastatic Breast Cancer

计划入组 18 人 · 首次发布于 2024 年 11 月 15 日

ESR1 Mutations in Asian ER+ Metastatic Breast Cancer on Hormonal Therapy-based Treatments

计划入组 123 人 · 首次发布于 2019 年 12 月 27 日

undisclosed epigenetic target therapeutic (metastatic breast cancer)

ET-1002

12A6-DM1

JAPAN BREAST CANCER RESEARCH GROUP

Japan

ANZ BREAST CANCER TRIALS GROUP LIMITED

Australia

International Breast Cancer Research Foundation

United States

EMERALD Trial Data Reveals Duration of Prior CDK4/6 Inhibitor Therapy as Key Predictor for Elacestrant Success in ESR1-Mutant Breast Cancer

Athira Pharma Secures $236 Million Financing and Exclusive Rights to Lasofoxifene for ESR1-Mutant Metastatic Breast Cancer

FDA Grants Accelerated Approval to AstraZeneca's Camizestrant (Etcamah) for ESR1-Mutant Metastatic Breast Cancer